Aequus, Medicom Healthcare to Jointly Advance Ophthalmology Products into the US

Aequus announced the signing of a term sheet to co-commercialize a portfolio of products in the US with Medicom Healthcare, a United Kingdom based pharmaceutical company with a focus on preservative free therapies in ophthalmology.

Under the proposed agreement, Aequus and Medicom will jointly commercialize Medicom’s range of preservative free ophthalmics in the United States of America. The companies will be working together for the first part of 2020, prioritizing programs and developing commercialization plans for the selected programs.

"The structure of the deal is akin to a joint venture, with revenues shared equally and investments and contributions made by each party reconciled through a joint P&L. There are no upfront requirements or commitments on spend and there will be a diligence phase to assess and prioritize which programs to move forward with from Medicom’s portfolio," said Doug Janzen, CEO and Chairman, Aequus Pharmaceuticals. "This sets us up for success as we plan our entry into the largest therapeutic market in the world."

"Medicom Healthcare is well poised to be one of the leading suppliers of Preservative Free ophthalmics globally. Our core belief is in "Preservative Free for Everyone," Simon Martin, Founder and CEO of Medicom Healthcare and former Head of Novartis Global Ophthalmology Franchise said. "The science is clear that non-preserved eye medicines are more beneficial than preserved and our rich portfolio will benefit US patients as we commercialize products with Aequus. Our initial commercial strategy will be to work with Insurers, Pharmacy Benefit Managers (PBM’s) and Business to Business (B2B) relationships to begin generating US revenues in 2020 without building a large infrastructure. We expect our infrastructure will be very light and highly focused on managed markets."

The first products launched in the US may include:

• The Evolve® line of preservative free dry eye products;
• A preservative free prescription product for the treatment of open angle glaucoma;
• A range of supporting diagnostics.

"We are tremendously excited about this next stage in the growth of Aequus, while deepening the growing strategic relationship with Medicom," said Doug Janzen CEO and Chairman of Aequus. "Both Aequus and Medicom are successfully growing and gaining market share for their ophthalmology products in Canada and the UK respectfully, and we are excited to jointly leverage our learnings and ophthalmic relationships as we approach this significant market. The best way to grow our business is to take existing knowledge and expertise into bigger markets and to do this with trusted partners."

"Our alliance with Aequus allows us to reach the patients we need to serve. Medicom Healthcare’s commitment to elevate the awareness, affordability and availability of eye care globally is echoed by our dedication to realize a world that is ‘preservative free for everyone’," Christian Martin, Managing Director of Medicom Healthcare said.

Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the reproduced articles,

please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.